Axelar initiates Phase I/II brain tumour study of AXL1717 in US
The study designed to assess the investigational drug AXL1717 in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma) is conducted at the Rush University Medical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.